RS64032B1 - Metoda lečenja urotelnog raka donjeg trakta - Google Patents

Metoda lečenja urotelnog raka donjeg trakta

Info

Publication number
RS64032B1
RS64032B1 RS20230163A RSP20230163A RS64032B1 RS 64032 B1 RS64032 B1 RS 64032B1 RS 20230163 A RS20230163 A RS 20230163A RS P20230163 A RSP20230163 A RS P20230163A RS 64032 B1 RS64032 B1 RS 64032B1
Authority
RS
Serbia
Prior art keywords
urothelial cancer
treating lower
lower tract
tract urothelial
treating
Prior art date
Application number
RS20230163A
Other languages
English (en)
Inventor
Dennis Giesing
Christopher Cutie
Purnanand Sarma
Cheryl Larrivee-Elkins
Christopher Searcy
Vikas Agarwal
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of RS64032B1 publication Critical patent/RS64032B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/02General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0216Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
RS20230163A 2016-05-06 2017-05-05 Metoda lečenja urotelnog raka donjeg trakta RS64032B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662333151P 2016-05-06 2016-05-06
US201762443614P 2017-01-06 2017-01-06
PCT/US2017/031445 WO2017193098A1 (en) 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer
EP17793523.6A EP3452053B1 (en) 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer

Publications (1)

Publication Number Publication Date
RS64032B1 true RS64032B1 (sr) 2023-04-28

Family

ID=60203435

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20230163A RS64032B1 (sr) 2016-05-06 2017-05-05 Metoda lečenja urotelnog raka donjeg trakta

Country Status (22)

Country Link
US (1) US20190388338A1 (sr)
EP (2) EP3452053B1 (sr)
JP (3) JP2019514970A (sr)
KR (2) KR102435709B1 (sr)
CN (1) CN109475571A (sr)
AU (1) AU2017261371B2 (sr)
BR (1) BR112018072551A2 (sr)
CA (1) CA3023274A1 (sr)
ES (1) ES2940227T3 (sr)
FI (1) FI3452053T3 (sr)
HR (1) HRP20221544T1 (sr)
HU (1) HUE060965T2 (sr)
IL (2) IL295592A (sr)
LT (1) LT3452053T (sr)
MX (2) MX2018013432A (sr)
PL (1) PL3452053T3 (sr)
PT (1) PT3452053T (sr)
RS (1) RS64032B1 (sr)
RU (2) RU2022100624A (sr)
SG (2) SG11201809838VA (sr)
SI (1) SI3452053T1 (sr)
WO (1) WO2017193098A1 (sr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
EP3658153A4 (en) 2017-07-25 2021-04-21 TARIS Biomedical LLC METHOD OF TREATMENT OF TUMOR METASTASIS
KR20200085822A (ko) 2017-11-08 2020-07-15 타리스 바이오메디컬 엘엘씨 젬시타빈을 사용한 방광암의 치료 및 유지 요법의 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
KR101710148B1 (ko) 2009-06-26 2017-02-27 타리스 바이오메디컬 엘엘씨 이식가능한 약물전달 디바이스에 사용되기 위한 고체 약물 정제
AU2010339821B2 (en) 2009-12-17 2015-02-19 Taris Biomedical Llc Implantable device with intravesical tolerability and methods of treatment
BR112012030699A2 (pt) * 2010-06-02 2016-09-13 Abraxis Bioscience Llc métodos para tratar câncer de bexiga
EP2600800B1 (en) 2010-08-05 2020-09-30 TARIS Biomedical LLC Ureteral stent drug delivery device and kit
JP6043730B2 (ja) 2011-02-04 2016-12-14 タリス バイオメディカル エルエルシー 低溶解性薬物の制御された放出のための植込み型装置
JP6639228B2 (ja) * 2012-03-29 2020-02-05 アルター・バイオサイエンス・コーポレーション 新生物を治療するための方法
SG11201501483XA (en) 2012-08-31 2015-03-30 Taris Biomedical Llc Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine
AU2013308464B2 (en) 2012-08-31 2018-02-01 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin
US10137287B2 (en) 2013-03-05 2018-11-27 Taris Biomedical Llc Drug delivery devices and methods for controlled drug release through device orifice
MX2015012367A (es) 2013-03-15 2016-05-31 Taris Biomedical Llc Dispositivos de suministro de farmacos con un componente permeable al farmaco y metodos.
MX2021001657A (es) 2013-03-15 2022-04-21 Taris Biomedical Llc Dispositivos de administración de medicamentos y métodos para administración de medicamentos.
AU2014309012B2 (en) 2013-08-19 2019-03-14 Taris Biomedical Llc Multi-unit drug delivery devices and methods
RS63675B1 (sr) * 2014-03-06 2022-11-30 Taris Biomedical Llc Sistemi za isporuku leka i metode za lečenje raka bešike gemcitabinom
KR102391761B1 (ko) 2014-06-26 2022-04-27 타리스 바이오메디컬 엘엘씨 탄성 폴리머-약물 매트릭스 시스템을 포함하는 방광내 약물 전달 장치 및 방법
JP7425534B2 (ja) 2015-04-23 2024-01-31 タリス バイオメディカル エルエルシー 薬物透過性構成要素を有する薬物送達デバイス及び方法

Also Published As

Publication number Publication date
KR20190005204A (ko) 2019-01-15
CA3023274A1 (en) 2017-11-09
FI3452053T3 (fi) 2023-04-12
RU2022100624A (ru) 2022-02-09
WO2017193098A1 (en) 2017-11-09
LT3452053T (lt) 2023-02-10
PT3452053T (pt) 2023-03-03
SI3452053T1 (sl) 2023-03-31
JP2022009327A (ja) 2022-01-14
RU2018142908A3 (sr) 2020-08-31
HRP20221544T1 (hr) 2023-02-17
HUE060965T2 (hu) 2023-04-28
PL3452053T3 (pl) 2023-05-08
MX2018013432A (es) 2019-08-12
AU2017261371A1 (en) 2018-12-13
JP2024028881A (ja) 2024-03-05
KR20220123317A (ko) 2022-09-06
EP4209221A1 (en) 2023-07-12
MX2021013461A (es) 2021-12-10
SG11201809838VA (en) 2018-12-28
RU2018142908A (ru) 2020-06-08
ES2940227T3 (es) 2023-05-04
IL262746B (en) 2022-09-01
RU2764747C2 (ru) 2022-01-20
BR112018072551A2 (pt) 2019-02-19
IL295592A (en) 2022-10-01
EP3452053A4 (en) 2019-12-25
SG10201913416PA (en) 2020-03-30
JP2019514970A (ja) 2019-06-06
EP3452053B1 (en) 2022-12-14
US20190388338A1 (en) 2019-12-26
AU2017261371B2 (en) 2023-07-06
EP3452053A1 (en) 2019-03-13
CN109475571A (zh) 2019-03-15
IL262746A (en) 2018-12-31
KR102435709B1 (ko) 2022-08-25

Similar Documents

Publication Publication Date Title
HK1258098A1 (zh) 治療癌症的方法
HK1251408A1 (zh) 治療癌症的方法
ZA201804227B (en) Methods of treating cancer
IL263925A (en) Methods of treating ovarian cancer
IL275663A (en) Cancer treatment methods
HK1252272A1 (zh) 使用抗ox40抗體治療癌症的方法
IL262005A (en) Methods of treating cancer in children
SG11201607130RA (en) Combination method for treatment of cancer
IL262342A (en) Cancer treatment methods
ZA201808258B (en) Methods of treating pancreatic cancer
HK1251927A1 (zh) 用於治療癌症的新穎生物標記和方法
ZA201908539B (en) Method of treatment of cancer
IL263835A (en) Exosome-guided treatment of cancer
IL262746A (en) A method for treating urothelial cancer in the lower system
SG11202005163PA (en) Methods of treating cancer
GB201717945D0 (en) Method for treatment of cancer
IL269123A (en) Methods of treating cancer
GB201510197D0 (en) Method of treating ovarian cancer
GB201622214D0 (en) treatment of cancer
GB201604621D0 (en) Treatment of cancer
GB201604293D0 (en) Treatment of cancer